Fig. 1 | Nature Communications

Fig. 1

From: LinCCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade

Fig. 1

HSC co-transfer increases overall survival in brain tumors refractory to PD-1. a Intracranial KR158B glioma was treated with either no treatment, HSCs only, PD-1 only, or the combination HSC + PD-1 (n = 7 mice/group; Gehan–Breslow–Wilcoxon statistical test; *n/s p = 0.3000, *p = 0.0024 **p = 0.0005). b Cerebellar Ptc medulloblastoma was also treated with either no treatment, HSCs only, PD-1 only, HSC + PD-1 (n = 7 mice/group; Gehan–Breslow–Wilcoxon statistical test) *n/s p = 0.476, *p = 0.0006, **p = 0.0085. c GREAT mice with established KR158B tumors received either no treatment, HSCs only, PD-1 only, or HSC + PD-1. Tumors were excised and analyzed for relative expression of YFP using flow cytometry to compare relative YFP+ CD3+ expression in mice that received HSC + PD-1 relative to PD-1 only (*p = 0.0079, Mann–Whitney test; n = 5 mice/group). d GREAT mice with established KR158B tumors received either no treatment, HSCs only, PD-1 only, or HSC + PD-1. Tumor draining lymph nodes were excised and analyzed for relative expression of YFP using flow cytometry to compare relative YFP+ CD3+ expression in mice that received HSC + PD-1 only relative to PD-1 only (*p = 0.0079, Mann–Whitney test; n = 5 mice/group). e RNA was extracted from the same tumors as in panel C and RT2 PCR Array for Cancer Inflammation and Immunity Crosstalk was performed (n = 3 tumors/group). This figure is representative of relative expression of genes associated with T-cell activation and immunosuppressive tumor microenvironments that express >2-fold difference relative to housekeeping genes. All error bars represent s.e.m.

Back to article page